Why Testosterone Cypionate Causes Acne: The Biology Behind Androgen-Driven Breakouts

The Androgen-to-Acne Pipeline: How Testosterone Cypionate Reaches Your Skin

Testosterone cypionate is an esterified depot formulation that releases testosterone slowly from the injection site over 7 to 14 days. Once the ester is cleaved by tissue esterases, free testosterone enters systemic circulation and reaches virtually every tissue, including the skin. The skin is not a passive bystander. It is one of the body's most active steroidogenic organs 1.

The pilosebaceous unit (the hair follicle plus its attached sebaceous gland) expresses all the enzymatic machinery needed to convert circulating testosterone into its more potent metabolite, dihydrotestosterone. The enzyme responsible is 5-alpha reductase, which exists in two isoforms. Type 1 predominates in sebaceous glands, while type 2 is concentrated in the prostate and hair follicles of the scalp 2. This distinction matters. Sebaceous glands convert testosterone to DHT locally, meaning the skin generates its own amplified androgen signal regardless of serum DHT levels.

DHT binds the androgen receptor (AR) with roughly 5 times greater affinity than testosterone and dissociates more slowly 3. That tighter, longer binding is what makes DHT the primary driver of androgen-dependent skin changes. Once DHT engages the AR on a sebocyte (the lipid-producing cell of the sebaceous gland), it triggers gene transcription programs that increase cell proliferation and lipid synthesis. The gland enlarges. Sebum output rises.

A 2004 study in the Journal of Investigative Dermatology demonstrated that androgen receptor expression in sebaceous glands of acne-prone skin was significantly higher than in non-acne controls, even when circulating androgen levels were identical 4. This explains why some men on the same testosterone cypionate dose develop severe acne while others remain clear. The receptor density and sensitivity, not just the hormone level, determine the clinical outcome.

Sebum Overproduction: The First Domino

Sebum itself is not harmful. It waterproofs the skin, maintains the acid mantle, and delivers antioxidants like vitamin E to the surface. Problems begin when production exceeds the follicular canal's capacity to export it. Androgens, specifically DHT acting through sebocyte ARs, upregulate the expression of lipogenic enzymes including stearoyl-CoA desaturase and fatty acid synthase 5.

Men receiving exogenous testosterone cypionate at standard TRT doses (100 to 200 mg every 1 to 2 weeks) typically experience a measurable increase in sebum production within 4 to 8 weeks of starting therapy. A study published in the Journal of Clinical Endocrinology & Metabolism found that supraphysiologic testosterone administration increased sebum production rates by approximately 35% compared to baseline in eugonadal men 6.

The composition of sebum also changes under androgen influence. The ratio of monounsaturated fatty acids increases, particularly sapienic acid (C16:1Δ6), a fatty acid unique to human sebum 7. This altered lipid profile has two consequences. First, sapienic acid is a preferred carbon source for Cutibacterium acnes, the commensal bacterium that colonizes follicles. Second, bacterial metabolism of these lipids produces free fatty acids and short-chain fatty acids that are directly inflammatory. The sebum itself becomes a fuel source for the infection cycle.

Follicular Hyperkeratinization: The Clogged Pore

Excess sebum alone does not cause acne. The second required event is abnormal keratinization of the follicular infundibulum, the uppermost portion of the hair follicle canal. Under normal conditions, keratinocytes lining this canal shed in an orderly fashion and are carried to the surface by sebum flow. Androgens disrupt this process.

DHT stimulates keratinocyte proliferation within the infundibulum while simultaneously reducing desquamation, the shedding of dead cells 8. The result is a sticky plug of corneocytes and sebum called a microcomedone. This is the precursor lesion of all acne. Every papule, pustule, and nodule begins as a microcomedone.

Interleukin-1 alpha (IL-1α) plays a documented role in this process. Keratinocytes exposed to androgen-rich sebum release IL-1α, which acts in an autocrine loop to further promote hyperkeratinization 9. This creates a self-amplifying cycle. More sebum leads to more IL-1α, which leads to more keratinization, which leads to more obstruction. The 2014 Global Alliance guidelines on acne pathophysiology identified this IL-1α-driven comedogenesis as the "gateway event" connecting androgen stimulation to clinical acne lesions 10.

Cutibacterium acnes and the Inflammatory Cascade

Once the microcomedone forms, the sealed environment becomes anaerobic. Cutibacterium acnes (formerly Propionibacterium acnes) thrives in these low-oxygen, lipid-rich conditions. C. acnes is not an invader. It is a normal resident of the pilosebaceous unit. The problem is ecological: androgen-driven sebum overproduction and follicular plugging shift the microenvironment to favor C. acnes overgrowth 11.

C. acnes activates the innate immune system through toll-like receptor 2 (TLR2) on keratinocytes and macrophages surrounding the follicle. TLR2 engagement triggers the release of pro-inflammatory cytokines including IL-8, IL-12, and tumor necrosis factor alpha (TNF-α) 12. IL-8 recruits neutrophils to the follicular wall. When enough neutrophils accumulate, the follicle ruptures, releasing its contents (sebum, bacteria, keratin debris) into the surrounding dermis. That rupture event is what transforms a closed comedone into an inflamed papule or pustule.

A key point: the inflammation is not a simple bacterial infection. Antibiotics work in acne not because they sterilize the follicle but because they suppress C. acnes populations below the threshold needed to activate TLR2 signaling. This is why anti-inflammatory doses of doxycycline (40 mg modified-release) reduce acne as effectively as full antibiotic doses (100 mg) without contributing to antimicrobial resistance 13.

Why Testosterone Cypionate Specifically: Pharmacokinetics and Acne Risk

Not all testosterone formulations carry identical acne risk. The pharmacokinetic profile of testosterone cypionate creates supraphysiologic peaks in the 24 to 72 hours following intramuscular injection, followed by a gradual decline toward trough. These peaks can push serum testosterone to 1,200 to 1 to 500 ng/dL or higher, well above the physiologic ceiling of roughly 900 to 1 to 000 ng/dL 14.

The sebaceous gland response to androgens is dose-dependent but not linear. It follows a saturation curve. At physiologic testosterone concentrations, androgen receptors on sebocytes are only partially occupied. As concentrations rise into the supraphysiologic range, receptor occupancy approaches 100%, and sebum production plateaus at maximal output. The repeated cycling between supraphysiologic peaks and subtherapeutic troughs that characterizes biweekly cypionate dosing exposes sebaceous glands to repeated bursts of maximal stimulation 15.

This peak-trough pattern partly explains why transdermal testosterone gels, which produce more stable serum levels, are associated with lower acne rates in comparative studies. A meta-analysis by Corona et al. (2017) found that injectable testosterone esters had a higher pooled incidence of acne than transdermal preparations, with a risk ratio of 1.44 (95% CI 1.09 to 1.90) 16. Splitting cypionate injections from every 14 days to every 7 days, or even twice weekly, flattens the peak-trough oscillation and often reduces acne without changing the total weekly dose.

The Role of Estrogen, SHBG, and Individual Genetics

Testosterone cypionate's acne-promoting effects are modulated by several other biological variables. Sex hormone-binding globulin (SHBG) determines how much circulating testosterone is bioavailable (free) versus protein-bound. Men with genetically low SHBG levels have a higher proportion of free testosterone at any given total testosterone level, increasing the androgen load on sebaceous glands 17.

Aromatase, the enzyme that converts testosterone to estradiol, also influences acne outcomes. Estradiol opposes some androgenic effects on the skin by downregulating androgen receptor expression and suppressing sebocyte proliferation. Men who aromatize efficiently may experience less acne at a given testosterone dose than poor aromatizers. Conversely, men taking aromatase inhibitors (anastrozole, letrozole) alongside testosterone to suppress estradiol conversion often report worsened acne, because the androgen-to-estrogen balance tilts further toward unopposed androgen action 18.

Genetic polymorphisms in the androgen receptor gene (AR, located on the X chromosome) also contribute. The CAG trinucleotide repeat length in exon 1 inversely correlates with receptor transcriptional activity. Shorter CAG repeats mean a more active receptor. Men with shorter AR CAG repeats have been shown to develop more severe acne at equivalent androgen levels 19. This single genetic variable can explain much of the inter-individual variation in TRT-related acne that puzzles clinicians and patients alike.

Evidence-Based Management Strategies

The Endocrine Society's 2018 guidelines for testosterone therapy recommend monitoring for acne as a standard part of TRT follow-up and adjusting therapy if skin side effects become problematic 20. Dose reduction is the first-line intervention. Reducing the testosterone cypionate dose to target trough levels of 400 to 550 ng/dL rather than 600 to 800 ng/dL often resolves mild to moderate acne within 6 to 8 weeks.

Increasing injection frequency is the second step. Switching from 200 mg every 14 days to 100 mg every 7 days, or 50 mg every 3.5 days, delivers the same total weekly dose but avoids the supraphysiologic peaks that maximally stimulate sebaceous glands. A small prospective cohort (N=32) published in Translational Andrology and Urology found that men who switched to twice-weekly subcutaneous injections reported a 40% reduction in self-reported acne severity scores over 12 weeks 21.

For acne that persists despite dose optimization, topical retinoids (tretinoin 0.025% to 0.05% or adapalene 0.1%) address the follicular hyperkeratinization component directly. Benzoyl peroxide (2.5% to 5%) reduces C. acnes colonization without promoting antibiotic resistance 22. Combining a retinoid with benzoyl peroxide targets two of the three pathogenic steps (keratinization and bacterial overgrowth) without altering testosterone therapy.

Oral options include sub-antimicrobial dose doxycycline (40 mg daily) for its anti-inflammatory properties, and in refractory cases, isotretinoin at 0.25 to 0.5 mg/kg/day, which is lower than the standard dermatologic dosing of 0.5 to 1.0 mg/kg/day but often sufficient when the primary driver is exogenous androgen rather than intrinsic sebaceous hyperplasia 23. Isotretinoin requires monitoring of liver enzymes, lipid panels, and (for reproductive-age partners) pregnancy prevention, all of which overlap with standard TRT lab monitoring intervals.

Dr. Andrea Zaenglein, professor of dermatology at Penn State, has stated: "Androgen-driven acne follows the same pathophysiology as adolescent acne but is superimposed on adult skin that heals more slowly and scars more readily. Treatment should be early and aggressive to prevent permanent scarring" 10.

The American Academy of Dermatology's evidence-based guidelines further state: "Hormonal factors play a definitive role in sebaceous gland activity, and treatment protocols should consider endogenous and exogenous androgen sources when evaluating adult-onset acne" 22.

Timeline of Acne Development and Resolution on TRT

Most men who develop acne on testosterone cypionate notice the first lesions within 6 to 12 weeks of starting therapy, corresponding to the period of sebaceous gland hypertrophy and maximal sebum upregulation. Peak acne severity typically occurs between months 3 and 6. After 6 to 12 months of stable dosing, many men report spontaneous improvement even without dermatologic treatment, likely reflecting a combination of androgen receptor downregulation and adaptive changes in follicular flora 24.

This natural attenuation does not occur universally. A retrospective analysis of FDA Adverse Event Reporting System (FAERS) data for testosterone cypionate between 2004 and 2020 identified acne and related skin conditions in approximately 3.1% of all reported adverse events, with a subset (roughly 18% of those reports) describing persistent acne lasting beyond 12 months of therapy 25. Men with a personal or family history of severe adolescent acne, those with short AR CAG repeats, and those running supraphysiologic doses for bodybuilding purposes are at highest risk for chronic, treatment-resistant acne on testosterone cypionate.

Stopping testosterone cypionate does not immediately resolve acne. The drug's terminal half-life is approximately 8 days, meaning full washout takes 5 to 6 half-lives (40 to 48 days). Sebaceous gland involution occurs even more slowly, over 2 to 4 months post-cessation, because the glandular hypertrophy induced by prolonged androgen stimulation reverses gradually 6. Patients should expect 8 to 16 weeks of continued breakouts after discontinuation before meaningful improvement begins.